Genenta & Anemocyte Announce New DNA Production Partnership
Genenta Science and Anemocyte have expanded their partnership to deliver an off-the-shelf lentiviral vector plasmid DNA platform, making Genenta’s...
AI Drug Discovery AstraZeneca BIO-Europe Spring 2026 biopharma M&A biopharma strategy biotech funding biotech strategy business development cancer immunotherapy China Biotech CNS Pipeline Strategy competitive intelligence Disease-Modifying Therapy Drug Pricing Strategy eClinical Tech News Eli Lilly Emerging Markets FDA Approval FDA Priority Review HER2 Oncology immuno-oncology immunology licensing deals Lifecycle Management Market Access Medtronic MSS colorectal cancer Novo Nordisk Obesity/GLP-1 Obesity Drug Market Obesity Market Oncology Pipeline Patent Cliff Priority Review Voucher pulmonary hypertension Rare Disease Regeneron respiratory biologics Roche Sanofi series A funding Teva Pharmaceuticals Type 1 Diabetes Type 2 Diabetes venture capital
No videos found.
Genenta Science and Anemocyte have expanded their partnership to deliver an off-the-shelf lentiviral vector plasmid DNA platform, making Genenta’s...
Health Canada has granted a Notice of Compliance with Conditions for Leqembi (lecanemab) for adults with mild cognitive impairment...
Novartis has agreed to acquire Avidity Biosciences for $12 billion in cash, consolidating control of a late-stage pipeline built...
Galapagos will present new in vitro pharmacology data for its selective TYK2 inhibitor, GLPG3667, at ACR Convergence 2025 in...
Rani Therapeutics has closed a $60.3 million oversubscribed private placement led by Samsara BioCapital, structured as common stock and...
Sobi North America is spotlighting 15 presentations at ACR Convergence 2025, featuring new Phase 3 analyses for its investigational...
Novartis will deliver 27 presentations at ACR Convergence 2025, headlined by late-breaking, pivotal Phase III results from the replicate...
Enzon Pharmaceuticals and Viskase Companies have amended their previously announced all-stock merger, resetting ownership so Viskase holders will own...
Supernus Pharmaceuticals will report its third-quarter 2025 financial and business results after market close on November 4, with a...
Teva has signed a licensing and supply agreement with Prestige Biopharma to commercialize Tuznue, a biosimilar of Herceptin (trastuzumab),...
